CERTIFICATE OF ANALYSIS

PuriLab Analytical

Retatrutide 20 mg

RT-2026-148 Lot RT20261029 Analyzed November 20, 2026

TIMELINE

ORDERED
November 16, 2026

RECEIVED
November 19, 2026

ANALYZED
November 20, 2026

SAMPLE

NAME
Retatrutide 20 mg

EXPECTED
Retatrutide

AMOUNT
1 vial, lyophilized powder

TESTING

CLIENT
Umbrella Peptide Corp.

TEST TYPE
Content & purity

METHOD
HPLC-UV

GROUP TEST

VIALS TESTED
1 vial, shared result

CONTRIBUTORS
5 people

SHARED BY
Matrix, Gloria Dominguez, Craig Jenkins, Peninsula LP, Ronnie Folomu

CONTENT, HOW MUCH IS IN IT

19.27 mg

Label claim: 20 mg


PURITY, HOW CLEAN IT IS

98.3%

Measured, not estimated. Purity is calculated from the full chromatogram shown above.

CHROMATOGRAM

HPLC-UV



- 13.43 min, Retatrutide, 98.3%

ANALYST COMMENTS

White lyophilized powder, pink-cap vial, received sealed.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: November 20, 2026

VERIFICATION CODE

RT-M4VO-09EZ

Verify at purilab.org/verify/RT-M4VO-09EZ

SCAN TO VERIFY

RT-M4VO-09EZ

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.